Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

NCT05477576 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

338

Enrollment

INDUSTRY

Sponsor class

Conditions

GEP-NET
Gastroenteropancreatic Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor Disease
Neuroendocrine Tumors
Carcinoid
Carcinoid Tumor
Pancreatic NET

Interventions

DRUG: RYZ101
DRUG: Everolimus
DRUG: Sunitinib
DRUG: Octreotide
DRUG: Lanreotide

Sponsor

RayzeBio, Inc.